期刊文献+

血管紧张素Ⅱ-醛固酮诱导肾性高血压大鼠心肌肥厚发生:钙调神经磷酸酶抑制因子的作用 被引量:1

Expression of calcineurin inhibitor in myocardium in renovascular hypertensive rats
下载PDF
导出
摘要 目的:探讨一肾一夹肾性高血压大鼠模型中,心肌组织中钙调神经磷酸酶(CaN)抑制因子(calcineurin-inhibi-tor,Cain)表达的变化,以及血浆中相关活性因子的变化。方法:将21只健康雄性Wistar大鼠,随机分为3组(n=7),即假手术组、手术组(通过一肾一夹法复制肾性高血压大鼠)及螺内酯组:以螺内酯20 mg/(kg.d)灌胃;实验14 d后,大鼠称质量后抽血处死,分别计算左心室质量(LVW)、全心质量(HW)以及二者与体质量(BW)的比值。采用放射免疫测定法检测血浆醛固酮(Ald)及血管紧张素Ⅱ(AngⅡ)的含量。以蛋白印迹杂交的方法,测定心肌组织中Cain表达的变化。结果:与假手术组比较,手术组大鼠的LVW/BW及HW/BW比值显著增加(P<0.05)、血浆Ald和AngⅡ的水平、及Cain的表达的显著增加(P<0.01);而与手术组比较,螺内酯组大鼠的LVW/BW比值显著减少(P<0.05)、血浆AngⅡ的水平及Cain的表达均显著减少(P<0.01)。结论:通过一肾一夹手术,诱导机体内源性Ald和AngⅡ增加,导致大鼠心肌肥厚反应的发生。同时,机体内源性Cain表达的增加,以抑制CaN信号通路介导的心肌肥厚反应。螺内酯通过阻断Ald与其受体结合,可以抑制心肌肥厚的发生。 AIM : To investigate the expression of myocardial calcineurin inhibitor (Cain) in renal hypertensive rats and the changes of active related factors in plasma. METHODS: Twenty one male Wistar rats were randomly divided into three groups (n = 7) : sham operation group, operation group treated with traditional one kidney and one clamp operation, and spironolactone group treated with spironolactone [ 20 rag/( kg · day) ]. Angiotensin Ⅱ (Aug Ⅱ) and Ald levels in plasma were determined by radioimmunoassay. The expression of Cain in myocardium was determined by Western blot. RESULTS: Ald and AngⅡ levels, expression of Cain and activity of calcineurin in myocardium all increased in operation group compared with those in sham operation group. Ang Ⅱ level markedly decreased in spironolactone group compared with that in the operation group. Expression of myocardial Cain level and ealcineurin activity also decreased significantly. CONCLUSION: Internal Ald induces cardiac hypertrophy through a calcineurin-dependent signal pathway. The expression of internal Cain may be controlled by the activity of caleineurin.
出处 《心脏杂志》 CAS 2010年第2期161-163,共3页 Chinese Heart Journal
基金 "十.五"军队重点基金资助(02Z0010)
关键词 肾性高血压 心肌组织 钙调神经磷酸酶抑制因子 大鼠 renovascular hypertension myocardium caleineurin inhibitor
  • 相关文献

参考文献9

  • 1Bueno OF, van Rooij E, Molkentin JD, et al. Calcineurin and hypertrophic heart disease: novel insights and remaining questions [ J ]. Cardiovascular Res, 2002, 53 (4) :806 - 821.
  • 2Takeda R, Suzuki E, Takahashi M, et al. Calcineurin is critical for sodium-induced neointimal formation in normotensive and hypertensive rats [ J ]. Am J Physiol Heart Circ Physiol, 2008, 294 ( 6 ) : H2871 - H2878.
  • 3Sheng H, Zhu J, Wu X, et al. Angiotensin-converting enzyme inhibitor suppress activation of calcineurin in rermvascular hypertensive rats [ J ]. H:ypertens Res, 2007, 30 (12) : 1247 - 1254.
  • 4Hill JA, Rothermel B, Yoo KD, et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy[ J ]. J Biol Chem, 2002, 277(12) :10251 - 10255.
  • 5Diedrichs H, Hagemeister J, Chi M, et al. Activation of the calcineurin/NFAT signaling cascade starts early in human hypertrophic myocardium[ J]. J lnt Med Res, 2007, 35(6) :803 -818.
  • 6Luedde M, Katus HA, Frey N. Novel molecular targets in the treatment of cardiac: tlypertrophy [ J ]. Recent Pat Cardiovasc Drug Discoy, 2006, 1(1):1-20.
  • 7Frank D, Kuhn C, van Eickels M, et al. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy[ J]. Circulation, 2007, 116 (22) :2587 - 2596.
  • 8Faul C, Dhume A, Schecter AD, et al. Protein kinase A, Ca2 +/ calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between Z-disc and the nucleus of cardiac myocytes [ J ]. Mol Cell Biol, 2007, 27 ( 23 ) :8215 - 8227.
  • 9Lemmens K, Segers VF, Demolder M, et al. Endogenous inhibitors of hypertrophy in concentric versus eccentric hypertrophy[ J]. Eur J Heart Fail, 2007, 9 ( 4 ) :352 - 356.

同被引文献36

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部